Impact BioMedical Inc. announced a significant milestone with the issuance of Canadian Patent #3,024,728 for its Linebacker™ technology platform. The patent is titled 'Electrophilically Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders' and is set to expire in May 2037. This marks the first Linebacker™ patent issued in Canada.
The patent includes claims for novel enhanced phenolic compounds and pharmaceutical compositions, as well as their uses in treating inflammatory related diseases. The Linebacker™ technology targets key pathways in the inflammatory process, with potential to reduce inflammation and mitigate conditions such as arthritis, asthma, and inflammatory bowel disease.
Frank D. Heuszel, CEO of Impact BioMedical, highlighted that the Canadian Inflammatory Disease Treatment Market was estimated at $7 billion in 2022. This patent issuance strengthens the company's growing intellectual property portfolio and underscores the commercial and therapeutic potential of its Linebacker™ technology in a new, substantial market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.